BioSig Technologies to Present at the Proactive Investors One2One Virtual Event on August 4, 2020

Rhea-AI Summary

BioSig Technologies (Nasdaq: BSGM) announced updates on its PURE EP(tm) System installations and the Phase 2 clinical study of merimepodib combined with remdesivir for COVID-19 patients. Kenneth L. Londoner, the Chairman and CEO, will present at the Proactive Investors One2One Virtual Event on August 4, 2020, at 1 PM ET. The company's technology aims to enhance ECG and intra-cardiac signal fidelity, while its subsidiary, ViralClear Pharmaceuticals, is developing merimepodib, an antiviral candidate previously explored for other conditions.

Westport, CT, July 30, 2020 (GLOBE NEWSWIRE) --

• Update on the PURE EP(tm) System installations and commercial progress
• Update on Phase 2 clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will present at the Proactive Investors One2One Virtual Event on August 4, 2020.

Event: Proactive Investors One2One Virtual Event
Date: Tuesday, August 4, 2020
Time: 1 PM ET
Registration link: https://www.proactiveinvestors.com/register/event_details/269 

For more information on the presentation please contact Andrew Ballou, Vice President, Investor Relations at aballou@biosigtech.com.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About ViralClear Pharmaceuticals, Inc. and Merimepodib (MMPD)
BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

FAQ

What is the date and time of BioSig Technologies' presentation at the Proactive Investors event?

The presentation is on August 4, 2020, at 1 PM ET.

What updates did BioSig Technologies announce in July 2020?

BioSig announced updates on the PURE EP(tm) System installations and the Phase 2 clinical study of merimepodib.

What is merimepodib and its significance to BioSig Technologies?

Merimepodib is an antiviral candidate being developed by BioSig's subsidiary, ViralClear Pharmaceuticals, for treating COVID-19.

What technology does BioSig Technologies specialize in?

BioSig specializes in a biomedical signal processing platform aimed at improving ECG and intra-cardiac signal fidelity.

Which company is presenting at the Proactive Investors One2One Virtual Event?

BioSig Technologies is presenting at this event.